cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.
作者信息
Brat Daniel J, Aldape Kenneth, Colman Howard, Figrarella-Branger Dominique, Fuller Gregory N, Giannini Caterina, Holland Eric C, Jenkins Robert B, Kleinschmidt-DeMasters Bette, Komori Takashi, Kros Johan M, Louis David N, McLean Catriona, Perry Arie, Reifenberger Guido, Sarkar Chitra, Stupp Roger, van den Bent Martin J, von Deimling Andreas, Weller Michael
机构信息
Department of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL, 60611, USA.
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
出版信息
Acta Neuropathol. 2020 Mar;139(3):603-608. doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.
Abstract
摘要
相似文献
1
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.cIMPACT-NOW更新5：IDH突变型星形细胞瘤的推荐分级标准和术语
Acta Neuropathol. 2020 Mar;139(3):603-608. doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29.
2
Prognostic stratification for IDH-wild-type lower-grade astrocytoma by Sanger sequencing and copy-number alteration analysis with MLPA.通过桑格测序和 MLPA 的拷贝数改变分析对 IDH 野生型低级别星形细胞瘤进行预后分层。
Sci Rep. 2021 Jul 13;11(1):14408. doi: 10.1038/s41598-021-93937-8.
3
Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.在预测世界卫生组织II/III级异柠檬酸脱氢酶（IDH）突变型星形细胞瘤患者的生存率方面，靶向拷贝数分析优于组织学分级。
Neuro Oncol. 2019 Jun 10;21(6):819-821. doi: 10.1093/neuonc/noz052.
4
Clinical implications of molecular analysis in diffuse glioma stratification.分子分析在弥漫性胶质瘤分层中的临床意义。
Brain Tumor Pathol. 2021 Jul;38(3):210-217. doi: 10.1007/s10014-021-00409-y. Epub 2021 Jul 15.
5
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.新型改良的 IDH 突变型星形细胞瘤分级系统。
Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.
6
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.有丝分裂指数阈值不能预测 IDH 突变型星形细胞瘤的临床结局。
J Neuropathol Exp Neurol. 2019 Nov 1;78(11):1002-1010. doi: 10.1093/jnen/nlz082.
7
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant.cIMPACT-NOW更新2：弥漫性中线胶质瘤、H3 K27M突变型以及弥漫性星形细胞瘤/间变性星形细胞瘤、IDH突变型的诊断澄清
Acta Neuropathol. 2018 Apr;135(4):639-642. doi: 10.1007/s00401-018-1826-y. Epub 2018 Mar 1.
8
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.成人 IDH 野生型星形细胞瘤在生物学和临床上可转化为其他肿瘤实体。
Acta Neuropathol. 2015 Sep;130(3):407-17. doi: 10.1007/s00401-015-1454-8. Epub 2015 Jun 19.
9
IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.异柠檬酸脱氢酶（IDH）突变型弥漫性和间变性星形细胞瘤在发病年龄上相似，生存差异不大：这是世界卫生组织面临的分级难题。
Acta Neuropathol. 2015 Jun;129(6):867-73. doi: 10.1007/s00401-015-1438-8. Epub 2015 May 12.
10
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.异柠檬酸脱氢酶（IDH）突变型星形细胞瘤亚组中快速进展为胶质母细胞瘤：全基因组分析
J Neurooncol. 2017 May;133(1):183-192. doi: 10.1007/s11060-017-2431-y. Epub 2017 Apr 18.
引用本文的文献
1
EGFR alteration is an adverse prognostic factor in IDH-mutant astrocytoma.表皮生长因子受体（EGFR）改变是异柠檬酸脱氢酶（IDH）突变型星形细胞瘤的不良预后因素。
Acta Neuropathol. 2025 Aug 19;150(1):20. doi: 10.1007/s00401-025-02928-w.
2
Integrated clinicopathological-radiomic-blood model for glioma survival prediction via machine learning: a multicenter cohort study.基于机器学习的胶质瘤生存预测综合临床病理-影像组学-血液模型：一项多中心队列研究
Neurosurg Rev. 2025 Jul 12;48(1):560. doi: 10.1007/s10143-025-03719-3.
3
Dissecting the Immunological Microenvironment of Glioma Based on IDH Status: Implications for Immunotherapy.基于异柠檬酸脱氢酶（IDH）状态剖析胶质瘤的免疫微环境：对免疫治疗的启示
Cells. 2025 Jul 7;14(13):1035. doi: 10.3390/cells14131035.
4
Molecular alterations in -mutant astrocytoma: A multi-institutional retrospective study.-突变型星形细胞瘤的分子改变：一项多机构回顾性研究。
Neurooncol Adv. 2025 Apr 28;7(1):vdaf088. doi: 10.1093/noajnl/vdaf088. eCollection 2025 Jan-Dec.
5
Cerebrospinal Fluid-Derived Genomic Alterations Tracking Glioma.脑脊液衍生基因组改变追踪胶质瘤
J Mol Neurosci. 2025 Jun 20;75(3):79. doi: 10.1007/s12031-025-02361-4.
6
Dissecting PTPN7-driven aggressiveness in IDH-wildtype astrocytomas: multi-omics, clinical validation, and spatial transcriptomics for prognostic insights.剖析IDH野生型星形细胞瘤中PTPN7驱动的侵袭性：多组学、临床验证及空间转录组学以获取预后见解
Discov Oncol. 2025 May 24;16(1):914. doi: 10.1007/s12672-025-02662-5.
7
SNUH methylation classifier for CNS tumors.用于中枢神经系统肿瘤的SNUH甲基化分类器。
Clin Epigenetics. 2025 Mar 12;17(1):47. doi: 10.1186/s13148-025-01824-0.
8
Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.多形性胶质母细胞瘤：对发病机制、关键信号通路及治疗策略的见解
Mol Cancer. 2025 Feb 26;24(1):58. doi: 10.1186/s12943-025-02267-0.
9
Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?4级异柠檬酸脱氢酶（IDH）突变型星形细胞瘤与IDH野生型胶质母细胞瘤的临床影像学与组织发生学比较分析——真的存在更恶性的一种吗？
Diagnostics (Basel). 2025 Feb 11;15(4):438. doi: 10.3390/diagnostics15040438.
10
cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics.cIMPACT-NOW更新9：关于全基因组DNA甲基化谱在中枢神经系统肿瘤诊断中的应用建议。
Neurooncol Adv. 2025 Jan 3;7(1):vdae228. doi: 10.1093/noajnl/vdae228. eCollection 2025 Jan-Dec.
本文引用的文献
1
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.CDKN2A 纯合缺失是弥漫性恶性 IDH 突变型神经胶质瘤的一个强烈不良预后因素。
Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.
2
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.IDH 突变型低级别（WHO 分级 II/III）星形细胞瘤可通过 CDKN2A、CDK4 和 PDGFRA 拷贝数改变进行风险分层。
Brain Pathol. 2020 May;30(3):541-553. doi: 10.1111/bpa.12801. Epub 2019 Dec 3.
3
Identification of subsets of -mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks.鉴定具有不同表观遗传和拷贝数改变以及分层临床风险的 - 突变胶质母细胞瘤亚群。
Neurooncol Adv. 2019 May-Dec;1(1):vdz015. doi: 10.1093/noajnl/vdz015. Epub 2019 Jul 17.
4
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.有丝分裂指数阈值不能预测 IDH 突变型星形细胞瘤的临床结局。
J Neuropathol Exp Neurol. 2019 Nov 1;78(11):1002-1010. doi: 10.1093/jnen/nlz082.
5
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas.FOCAD 缺失会影响微管组装、G2/M 期进程和星形细胞瘤患者的生存。
Acta Neuropathol. 2020 Jan;139(1):175-192. doi: 10.1007/s00401-019-02067-z. Epub 2019 Aug 31.
6
Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas.确定成人异柠檬酸脱氢酶（IDH）突变的II/III级星形细胞瘤中总拷贝数变异的预后阈值。
Acta Neuropathol Commun. 2019 Jul 26;7(1):121. doi: 10.1186/s40478-019-0778-3.
7
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.MTAP 缺失促进胶质母细胞瘤中的干性并赋予对嘌呤饥饿的独特易感性。
Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30.
8
Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas.在预测世界卫生组织II/III级异柠檬酸脱氢酶（IDH）突变型星形细胞瘤患者的生存率方面，靶向拷贝数分析优于组织学分级。
Neuro Oncol. 2019 Jun 10;21(6):819-821. doi: 10.1093/neuonc/noz052.
9
Integrated molecular characterization of IDH-mutant glioblastomas.IDH 突变型 glioblastomas 的综合分子特征。
Neuropathol Appl Neurobiol. 2019 Feb;45(2):108-118. doi: 10.1111/nan.12523. Epub 2018 Nov 15.
10
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".cIMPACT-NOW更新3：“弥漫性星形细胞胶质瘤，IDH野生型，具有胶质母细胞瘤分子特征，WHO四级”的推荐诊断标准。
Acta Neuropathol. 2018 Nov;136(5):805-810. doi: 10.1007/s00401-018-1913-0. Epub 2018 Sep 26.
Zotero 插件